Synthetic peptides of IL-1Ra and HSP70 have anti-inflammatory activity on human primary monocytes and macrophages: Potential treatments for inflammatory diseases

Nanomedicine. 2024 Jan:55:102719. doi: 10.1016/j.nano.2023.102719. Epub 2023 Nov 17.

Abstract

Chronic inflammatory diseases are increasing in developed societies, thus new anti-inflammatory approaches are needed in the clinic. Synthetic peptides complexes can be designed to mimic the activity of anti-inflammatory mediators, in order to alleviate inflammation. Here, we evaluated the anti-inflammatory efficacy of tethered peptides mimicking the interleukin-1 receptor antagonist (IL-1Ra) and the heat-shock protein 70 (HSP70). We tested their biocompatibility and anti-inflammatory activity in vitro in primary human monocytes and differentiated macrophages activated with two different stimuli: the TLR agonists (LPS + IFN-γ) or Pam3CSK4. Our results demonstrate that IL-1Ra and HSP70 synthetic peptides present a satisfactory biocompatible profile and significantly inhibit the secretion of several pro-inflammatory cytokines (IL-6, IL-8, IL-1β and TNFα). We further confirmed their anti-inflammatory activity when peptides were coated on a biocompatible material commonly employed in surgical implants. Overall, our findings support the potential use of IL-1Ra and HSP70 synthetic peptides for the treatment of inflammatory conditions.

Keywords: Inflammation; Inflammatory disorders; Innate immunity; Macrophages; Monocytes; Tethered peptides.

MeSH terms

  • Anti-Inflammatory Agents* / pharmacology
  • Anti-Inflammatory Agents* / therapeutic use
  • Humans
  • Interleukin 1 Receptor Antagonist Protein* / pharmacology
  • Interleukin 1 Receptor Antagonist Protein* / therapeutic use
  • Lipopolysaccharides / pharmacology
  • Macrophages / drug effects
  • Monocytes / drug effects
  • Peptides / pharmacology
  • Peptides / therapeutic use

Substances

  • Anti-Inflammatory Agents
  • Interleukin 1 Receptor Antagonist Protein
  • Lipopolysaccharides
  • Peptides